Foot-and-mouth disease primary prevention

Jump to navigation Jump to search

Foot-and-mouth disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Foot-and-mouth disease from other Diseases

Epidemiology and Demographics

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Foot-and-mouth disease primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

slides

Images

American Roentgen Ray Society Images of Foot-and-mouth disease primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Foot-and-mouth disease primary prevention

on Foot-and-mouth disease primary prevention

Foot-and-mouth disease primary prevention in the news

Blogs on Foot-and-mouth disease primary prevention

Directions to Hospitals Treating Foot-and-mouth disease

Risk calculators and risk factors for Foot-and-mouth disease primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Primary Prevention

Vaccination

File:Plum Island Animal Disease Center.jpg
Plum Island Animal Disease Center

Seven main types of Foot and Mouth Virus are believed to exist[1]. Like other viruses, the FMD virus continually evolves and mutates thus one of the difficulties in vaccinating against FMD is the huge variation between and even within serotypes. There is no cross-protection between serotypes (meaning that a vaccine for one serotype won't protect against any others) and in addition, two strains within a given serotype may have nucleotide sequences that differ by as much as 30% for a given gene. This means that FMD vaccines must be highly specific to the strain involved. Vaccination only provides temporary immunity that lasts from months to years.

Currently, the World Organisation for Animal Health recognizes countries to be in one of three disease states with regards to FMD: FMD present with or without vaccination, FMD-free with vaccination, and FMD-free without vaccination. Countries that are designated FMD-free without vaccination have the greatest access to export markets, and therefore many developed nations, including Canada, the United States, and the UK, work hard to maintain their currentFMD-free without vaccination status.

Many early vaccines used dead samples of FMD virus to inoculate animals. However, those early vaccines sometimes caused real outbreaks. In the 1970s, scientists discovered that a vaccine could be made using only a single key protein from the virus. The task was to produce such quantities of the protein that could be used in the vaccination. On June 18, 1981, the U.S. government announced the creation of a vaccine targeted against FMD; this was the world's first genetically engineered vaccine.

The North American FMD Vaccine Bank is housed at the United States Department of Agriculture's (USDA) Foreign Animal Disease Diagnostic Laboratory (FADDL) atPlum Island Animal Disease Center. The Center, located 1.5 miles off the coast of Long Island, NY, is the only place in the United States where scientists can conduct research and diagnostic work on highly contagious animal diseases such as FMD. Because of this limitation US companies working on FMD usually use facilities in other countries where such diseases are endemic.

References

  1. http://copus.org.uk/page.asp?id=1253 Foot and Mouth Virus Information

Template:WH Template:WS